Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis

8 páginas

Autores:: Romero Sánchez, Consuelo
Robinson, William H.
Tomooka, Beren H.
Londoño Patiño, John Darío
Valle Oñate, Rafael
Huang, Feng
Deng, Xiaohu
Zhang, Liyun
Yang, Chunhua
Tak Yan Yu, David

Tipo de recurso:

Fecha de publicación:: 2008

Institución:: Universidad de la Sabana

Repositorio:: Repositorio Universidad de la Sabana

Idioma:: eng

id	REPOUSABA2_52b5e29b31d46b69ea40406168710091
oai_identifier_str	oai:intellectum.unisabana.edu.co:10818/43203
network_acronym_str	REPOUSABA2
network_name_str	Repositorio Universidad de la Sabana
repository_id_str
spelling	Romero Sánchez, ConsueloRobinson, William H.Tomooka, Beren H.Londoño Patiño, John DaríoValle Oñate, RafaelHuang, FengDeng, XiaohuZhang, LiyunYang, ChunhuaTak Yan Yu, David9/4/2020 16:322020-09-04T21:32:19Z2008-06-20Romero-Sánchez, C., Robinson, W.H., Tomooka, B.H. et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 27, 1429–1435 (2008). https://doi.org/10.1007/s10067-008-0941-xhttps://pubmed.ncbi.nlm.nih.gov/18566849/https://link.springer.com/article/10.1007%2Fs10067-008-0941-x#citeashttp://hdl.handle.net/10818/4320310.1007/s10067-008-0941-x8 páginasAlthough most ankylosing spondylitis patients show an apparent clinical response to infliximab therapy, there is considerable individual variation. Because current clinical assessment relies heavily on subjective patient self-evaluation, biomarkers of high sensitivity and specificity are much needed. Here, we assessed potential biomarkers in 47 ankylosing spondylitis patients who received three standard pulses of infliximab. Before each infusion and at week 10, the following were measured: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), platelet count, serum levels of metalloproteinase-3 (MMP-3), and 22 different cytokines. We discovered that, 2 weeks after the first infusion, the combination of ESR, CRP, and platelet count distinguished responders from non-responders with 81.3% sensitivity and 72.7% specificity. The distinguishing power was much less when each acute phase reactant was used alone. Among the 22 cytokines, serum IL-1alpha was able to distinguish responders from non-responders at week 6, with sensitivity of 84.9% and specificity of 53.8%. Serum IL-1alpha was probably generated from the joint compartments, as synovial fluid levels were much higher than corresponding serum levels. Although infliximab infusions led to rapid and significant suppression of serum MMP-3 levels, serum MMP-3 levels did not distinguish responders from non-responders. Besides identifying potential biomarkers, our results also demonstrate the usefulness of using sensitivity and specificity to assess usefulness of potential biomarkers.application/pdfengClinical RheumatologyClinical Rheumatology volume 27, pages1429–1435(2008)Attribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/http://purl.org/coar/access_right/c_abf2Universidad de La SabanaIntellectum Repositorio Universidad de La SabanaAnkylosing spondylitisBiomarkersInfliximabIdentification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitisarticlepublishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://intellectum.unisabana.edu.co/bitstream/10818/43203/2/license_rdf4460e5956bc1d1639be9ae6146a50347MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-8498https://intellectum.unisabana.edu.co/bitstream/10818/43203/3/license.txtf52a2cfd4df262e08e9b300d62c85cabMD5310818/43203oai:intellectum.unisabana.edu.co:10818/432032022-05-10 05:20:33.99Intellectum Universidad de la Sabanacontactointellectum@unisabana.edu.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
dc.title.es_CO.fl_str_mv	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
title	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
spellingShingle	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis Ankylosing spondylitis Biomarkers Infliximab
title_short	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
title_full	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
title_fullStr	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
title_full_unstemmed	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
title_sort	Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis
dc.creator.fl_str_mv	Romero Sánchez, Consuelo Robinson, William H. Tomooka, Beren H. Londoño Patiño, John Darío Valle Oñate, Rafael Huang, Feng Deng, Xiaohu Zhang, Liyun Yang, Chunhua Tak Yan Yu, David
dc.contributor.author.none.fl_str_mv	Romero Sánchez, Consuelo Robinson, William H. Tomooka, Beren H. Londoño Patiño, John Darío Valle Oñate, Rafael Huang, Feng Deng, Xiaohu Zhang, Liyun Yang, Chunhua Tak Yan Yu, David
dc.subject.es_CO.fl_str_mv	Ankylosing spondylitis Biomarkers Infliximab
topic	Ankylosing spondylitis Biomarkers Infliximab
description	8 páginas
publishDate	2008
dc.date.issued.none.fl_str_mv	2008-06-20
dc.date.available.none.fl_str_mv	2020-09-04T21:32:19Z
dc.date.accessioned.none.fl_str_mv	9/4/2020 16:32
dc.type.en.fl_str_mv	article
dc.type.coarversion.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.hasVersion.es_CO.fl_str_mv	publishedVersion
dc.identifier.citation.es_CO.fl_str_mv	Romero-Sánchez, C., Robinson, W.H., Tomooka, B.H. et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 27, 1429–1435 (2008). https://doi.org/10.1007/s10067-008-0941-x
dc.identifier.other.none.fl_str_mv	https://pubmed.ncbi.nlm.nih.gov/18566849/ https://link.springer.com/article/10.1007%2Fs10067-008-0941-x#citeas
dc.identifier.uri.none.fl_str_mv	http://hdl.handle.net/10818/43203
dc.identifier.doi.none.fl_str_mv	10.1007/s10067-008-0941-x
identifier_str_mv	Romero-Sánchez, C., Robinson, W.H., Tomooka, B.H. et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 27, 1429–1435 (2008). https://doi.org/10.1007/s10067-008-0941-x 10.1007/s10067-008-0941-x
url	https://pubmed.ncbi.nlm.nih.gov/18566849/ https://link.springer.com/article/10.1007%2Fs10067-008-0941-x#citeas http://hdl.handle.net/10818/43203
dc.language.iso.es_CO.fl_str_mv	eng
language	eng
dc.relation.ispartofseries.none.fl_str_mv	Clinical Rheumatology volume 27, pages1429–1435(2008)
dc.rights.*.fl_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.coar.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.uri.*.fl_str_mv	http://creativecommons.org/licenses/by-nc-nd/4.0/
rights_invalid_str_mv	Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ http://purl.org/coar/access_right/c_abf2
dc.format.es_CO.fl_str_mv	application/pdf
dc.publisher.es_CO.fl_str_mv	Clinical Rheumatology
dc.source.es_CO.fl_str_mv	Universidad de La Sabana Intellectum Repositorio Universidad de La Sabana
institution	Universidad de la Sabana
bitstream.url.fl_str_mv	https://intellectum.unisabana.edu.co/bitstream/10818/43203/2/license_rdf https://intellectum.unisabana.edu.co/bitstream/10818/43203/3/license.txt
bitstream.checksum.fl_str_mv	4460e5956bc1d1639be9ae6146a50347 f52a2cfd4df262e08e9b300d62c85cab
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Intellectum Universidad de la Sabana
repository.mail.fl_str_mv	contactointellectum@unisabana.edu.co
_version_	1811952266078322688

Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis

Publicaciones similares